Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes
Table 1
The characteristics of patients and the effect of transient insulin intensive therapy with metformin on glycemic control and β-cell function.
Group
Group Asp (51)
Group Lis (48)
t value
value
Age (years)
51.08 ± 1.59
48.94 ± 1.68
0.927
0.356
BMI (kg/m2)
25.78 ± 0.41
24.82 ± 0.54
1.450
0.150
Weight (kg)
71.00 ± 12.18
74.80 ± 10.75
−1.630
0.106
The insulin does/day per kilo of weight (U/kg)
0.26 ± 0.02
0.29 ± 0.02
−0.632
0.529
The intensive treatment days (days)
10.04 ± 0.22
9.45 ± 0.31
1.581
0.117
Before intensive treatment
HbA1c (%)
10.71 ± 0.20
10.99 ± 0.23
−0.909
0.366
Fructosamine (μmol/L)
412.62 ± 12.53
427.65 ± 14.97
−0.775
0.44
Fasting plasma glucose (mmol/L)
10.65 ± 0.35
11.31 ± 0.44
−1.182
0.239
2 h postprandial glucose (mmol/L)
21.73 ± 0.57
21.24 ± 0.65
0.561
0.575
Fasting plasma C-peptide (pmol/L)
2.20 ± 0.13
3.23 ± 0.84
−1.254
0.212
2 h postprandial C-peptide (pmol/L)
4.46 ± 0.24
5.01 ± 0.38
−1.250
0.214
Fasting plasma insulin (mU/L)
7.71 ± 0.82
8.48 ± 0.64
−0.737
0.462
2 h postprandial insulin (mU/L)
19.75 ± 1.80
25.36 ± 3.29
−1.511
0.133
HOMA-IR
3.75 ± 0.42
4.26 ± 0.36
−0.927
0.356
HOMA-B
24.50 ± 3.00
26.41 ± 3.41
−0.421
0.674
After intensive treatment
HbA1c (%)
9.35 ± 0.18
9.24 ± 0.25
0.337
0.737
Fructosamine (μmol/L)
330.13 ± 7.42
322.51 ± 10.44
0.609
0.544
Fasting plasma glucose (mmol/L)
6.90 ± 0.26
6.81 ± 0.24
0.254
0.799
2 h postprandial glucose (mmol/L)
16.29 ± 0.49
15.38 ± 0.54
1.261
0.21
Fasting plasma C-peptide (pmol/L)
2.10 ± 0.16
2.21 ± 0.10
−0.591
0.555
2 h postprandial C-peptide (pmol/L)
8.63 ± 1.50
7.38 ± 0.43
0.785
0.434
Fasting plasma insulin (mU/L)
6.03 ± 0.50
6.99 ± 0.70
−1.131
0.26
2 h postprandial insulin (mU/L)
40.01 ± 3.97
40.15 ± 5.11
−0.022
0.981
HOMA-IR
1.86 ± 0.17
2.18 ± 0.27
−1.014
0.312
HOMA-B
42.73 ± 5.00
51.46 ± 6.52
−1.071
0.286
Data were presented as means ± SD. BMI: body mass index; HOMA-B: homeostasis model assessment-B; HOMA-IR: homeostasis model assessment-IR.
